Articles published by Asher Biotherapeutics, Inc.

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

May 21, 2026

From Asher Biotherapeutics, Inc.

Via GlobeNewswire

Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors

January 17, 2023

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Appoints Independent Director Elaine Sun to Its Board

January 05, 2023

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Presents New Preclinical Data at ASH Applying Cis-Targeted Cytokines to Enhance CAR-T Cell Therapies

December 12, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies

November 10, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022

November 04, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio to Present New Preclinical Data for Selective Support of CAR-T Cell Therapies by Cis-Targeted IL-2 and IL-21 Cytokines at ASH 2022

November 03, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

October 21, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022

October 05, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board

July 06, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer

June 13, 2022

From Asher Biotherapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.